NOVOCURE LTD's ticker is NVCR and the CUSIP is G6674U108. A total of 201 filers reported holding NOVOCURE LTD in Q1 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $7,836,000 | +58.6% | 162,667 | +10.2% | 0.01% | +42.9% |
| Q4 2018 | $4,942,000 | -67.0% | 147,609 | -48.4% | 0.01% | -22.2% |
| Q3 2018 | $14,982,000 | +241.3% | 285,930 | +103.9% | 0.01% | +80.0% |
| Q2 2018 | $4,390,000 | +56.7% | 140,253 | +9.1% | 0.01% | +25.0% |
| Q1 2018 | $2,802,000 | +32.7% | 128,553 | +23.0% | 0.00% | +33.3% |
| Q4 2017 | $2,112,000 | +1.8% | 104,530 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $2,075,000 | +15.0% | 104,530 | +0.3% | 0.00% | 0.0% |
| Q2 2017 | $1,804,000 | +125.5% | 104,265 | +5.5% | 0.00% | +200.0% |
| Q1 2017 | $800,000 | +6.5% | 98,799 | +3.3% | 0.00% | 0.0% |
| Q4 2016 | $751,000 | +11.4% | 95,674 | +21.2% | 0.00% | 0.0% |
| Q3 2016 | $674,000 | -28.6% | 78,933 | -2.5% | 0.00% | -50.0% |
| Q2 2016 | $944,000 | +486.3% | 80,929 | +628.2% | 0.00% | – |
| Q1 2016 | $161,000 | -17.0% | 11,114 | +27.9% | 0.00% | – |
| Q4 2015 | $194,000 | – | 8,688 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 350,884 | $26,344,000 | 8.01% |
| HARTLINE INVESTMENT CORP/ | 318,109 | $23,884,000 | 3.27% |
| Deep Track Capital, LP | 550,000 | $41,294,000 | 2.92% |
| MORGAN JESS S & CO INC | 43,975 | $3,302,000 | 2.03% |
| Taylor Frigon Capital Management LLC | 46,376 | $3,482,000 | 1.09% |
| Darsana Capital Partners LP | 258,937 | $19,441,000 | 0.90% |
| Private Harbour Investment Management & Counsel, LLC | 13,562 | $1,018,000 | 0.81% |
| Rhenman & Partners Asset Management AB | 120,387 | $9,610,000 | 0.64% |
| COURAGE CAPITAL MANAGEMENT LLC | 10,000 | $751,000 | 0.50% |
| Baillie Gifford | 9,615,168 | $721,906,000 | 0.40% |